Journal article

Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer

Aravind S Ravi Kumar, Nathan Lawrentschuk, Michael S Hofman

Current Opinion in Urology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020


PURPOSE OF REVIEW: Molecular imaging with PET/CT targeting the prostate-specific membrane antigen (PSMA) receptor is increasingly utilized in men with prostate cancer (PCa), with clinical indications now expanding beyond biochemical recurrence. PSMA PET/CT often detects sub-centimetre size pathologic nodes and low-volume bone marrow disease that are occult on conventional imaging when the lesion does not cause sclerosis or osteoblastic reaction in surrounding bone. This review focuses on recent evidence for PSMA PET/CT in initial disease staging. RECENT FINDINGS: Several recent studies including a large randomized trial have evaluated the clinical impact of PSMA PET/CT in initial staging of ..

View full abstract


Funding Acknowledgements

M.H. receives grant support from Movember, Prostate Cancer Foundation (PCF), Prostate Cancer Foundation of Australia (PCFA), Victorian Cancer Agency (VCA), Australian Government (Medical Research Future Fund) and the U.S. Department of Defence. He also acknowledges a Clinical Fellowship Award from the Peter MacCallum Foundation. He has received honorary and travel support from Janssen, Ipsen, and Sanofi Genzyme.